We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 27.30 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDNL
RNS Number : 0316D
Diurnal Group PLC
21 June 2019
21 June 2019
Diurnal Group plc
("Diurnal" or the "Company")
Change of Auditor
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, is pleased to announce that following the conclusion of a tender process overseen by the Company's audit committee, the Company has appointed PricewaterhouseCoopers LLP ("PwC") as the Company's independent auditor for the financial year ended 30 June 2019. The appointment of PwC as the Company's auditor for the financial year ended 30 June 2020 will be subject to approval by the Company's shareholders at the next Annual General Meeting due to be held in November 2019.
The Company's previous auditor, KPMG LLP, has confirmed to the Company that it is not aware of any circumstances connected with its termination as auditor that it considers should be brought to the attention of the Board, creditors or shareholders of the Company.
For further information, please visit www.diurnal.co.uk or contact: Diurnal Group plc +44 (0)20 3727 1000 Martin Whitaker, Chief Executive Officer Richard Bungay, Chief Financial Officer Panmure Gordon (UK) Limited (NOMAD and Joint Broker) +44 (0) 20 7886 2500 Corporate Finance: Freddy Crossley, Emma Earl Corporate Broking: James Stearns Cantor Fitzgerald Europe (Joint Broker) +44 (0)20 7894 7000 Corporate Finance: Philip Davies, William Goode, Michael Boot Healthcare Equity Sales: Andrew Keith FTI Consulting (Investor Relations) +44 (0)20 3727 1000 Simon Conway Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCLIFLARRILFIA
(END) Dow Jones Newswires
June 21, 2019 05:18 ET (09:18 GMT)
1 Year Diurnal Chart |
1 Month Diurnal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
